AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Genmab Reports Q2 2025 DARZALEX Sales of $3.539B, Up 27% YoY
ByAinvest
Wednesday, Jul 16, 2025 6:31 am ET1min read
Genmab reported net sales of DARZALEX (daratumumab) for Q2 2025 at $3,539 million, with royalties received on worldwide net sales from Johnson & Johnson. Sales totaled $2,017 million in the US and $1,521 million in the rest of the world. Genmab receives royalties on net sales under an exclusive worldwide license to J&J.
Genmab A/S (NASDAQ: GMAB) reported robust net sales of DARZALEX (daratumumab) for the second quarter of 2025, totaling USD 3,539 million. This significant performance was driven by strong sales of both the intravenous and subcutaneous (SC) versions of the drug, with the SC product, DARZALEX FASPRO®, contributing to the overall growth.The company's net sales in the United States reached USD 2,017 million, while sales in the rest of the world amounted to USD 1,521 million. Genmab receives royalties on net sales of DARZALEX under an exclusive worldwide license agreement with Johnson & Johnson (J&J), which further underscores the financial impact of these sales on Genmab's revenue.
Genmab's strong Q2 performance can be attributed to the growing demand for DARZALEX in the treatment of multiple myeloma and other indications. The company's ability to maintain a significant market share in this competitive landscape highlights its innovative approach to developing and commercializing antibody therapeutics.
Looking ahead, Genmab continues to focus on expanding its product pipeline and leveraging its proprietary antibody technology platforms to improve patient outcomes. The company's commitment to innovation and collaboration with leading pharmaceutical partners, such as J&J, positions it well for future growth.
References:
[1] https://finance.yahoo.com/news/ubs-maintains-buy-genmab-gmab-151402375.html
[2] https://www.nasdaq.com/articles/andrew-hill-dumps-38000-johnson-johnson-shares-q2-2025-exit
[3] https://www.globenewswire.com/news-release/2025/07/16/3116237/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-Second-Quarter-of-2025.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet